PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1)

Collectively, our findings identify the functional Pin1/Notch3 axis as an escape strategy from chemotherapy-induced cell death, thus suggesting a novel predictive role of the Pin1/Notch3 axis in the platinum response, which could be useful for implementing frontline treatments for HGSOC patients before recurrence.

Notably, silencing PIN1 expression significantly attenuated ZMIZ2-mediated activation of the PI3K/AKT signaling pathway and inhibited LUAD cell proliferation, migration and invasion. Collectively, our findings establish ZMIZ2 as a novel metastasis driver that orchestrates LUAD progression through PIN1-mediated PI3K/AKT pathway activation, providing a rationale for targeting this axis in precision oncology.

HBx-SENP1's role in regulating CSC-associated properties was examined in vitro (stemness expression, sphere formation, CD133+ cells, migration/invasion, and sorafenib sensitivity) and in vivo using an orthotopic xenograft model...Findings from this research highlight that HBx-induced SENP1 is crucial for promoting CSC-associated properties in HCC. SENP1 could serve as a novel biomarker of early tumor recurrence and metastasis, especially for HBV-related HCC.

Our findings suggest that Pin1 reshapes the immunosuppressive TME in MSS CRC through the NF-κB-CCL3-CCR5 axis, driving CRC progression and immunotherapy resistance. This pathway presents a potential target for overcoming immunotherapy resistance in MSS CRC.

In allograft models, host PIN1 was critical for normal growth of a subset of pancreatic cancer cell lines that are responsive to HGF signaling. Through the identification of changes to fibroblast activation state and crosstalk following PIN1 loss or inhibition, these data suggest that systemic targeting of PIN1 will suppress the pro-tumorigenic PDAC microenvironment and may differentially affect heterogeneous patient populations.

Future research must prioritize delineating common core pathways, structure-guided drug design, and biomarker-driven combination therapies. PIN1 inhibition represents a transformative approach to overcome resistance and improve outcomes across malignancies.

These findings highlight f-BRDP nanoparticles as a promising tumor-targeted therapeutic platform that overcomes the limitations of conventional therapeutics and advances precision nanomedicine. We believe that f-BRDP nanoparticles offer a novel approach to expanding the clinical applications of RA in targeted cancer therapy while addressing the limitations of carriers-mediated drug delivery.

PIN1 exhibits tumor-suppressive activity in LUAD and may serve as a promising biomarker for prognosis and therapeutic response. These findings underscore the context-dependent role of PIN1 and support further exploration of its mechanistic involvement in LUAD immunobiology and targeted therapy resistance.

Its unique ability to penetrate whole cell populations positions it as a promising approach for cancer therapy and as an enhancer for chemotherapy and immunotherapy. The findings suggest that HEX-1 holds the potential as a valuable addition to the armamentarium against CRC.

Thus, Pin1 is may have potential as a novel potential biomarker for tumor diagnosis and prognosis, as well as a promising anticancer target. The aim of the present review was to discuss the mechanism of Pin1 in tumors and recent research progress in this field.

This study confirmed that USP34 could upregulate PIN1 expression and SUMOylation, thereby inhibiting ferroptosis by suppressing the cGAS-STING pathway and in turn promoting the progression of cervical cancer.

Moreover, Pin1 inhibition combined with Pyk2 inhibition decreases myeloma burden both in vitro and in vivo. Altogether, our findings reveal the tumor-promoting role of Pin1 in MM and provide evidence that targeting Pin1 could be a therapeutic strategy for MM.